Koers Aurinia Pharmaceuticals Inc. Toronto S.E.
Aandelen
AUP
CA05156V1022
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 231 mln. 315 mln. 214 mln. | Omzet 2025 * | 282 mln. 386 mln. 262 mln. | Marktkapitalisatie | 729 mln. 998 mln. 678 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -40 mln. -54,74 mln. -37,17 mln. | Nettowinst (verlies) 2025 * | 50 mln. 68,42 mln. 46,46 mln. | EV/omzet 2024 * | 1,45 x |
Nettoliquiditeiten 2024 * | 395 mln. 541 mln. 367 mln. | Nettoliquiditeiten 2025 * | 448 mln. 613 mln. 416 mln. | EV/omzet 2025 * | 1 x |
K/w-verhouding 2024 * |
-39,2
x | K/w-verhouding 2025 * |
12,2
x | Werknemers | 300 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 92,47% |
Recentste transcriptie over Aurinia Pharmaceuticals Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Michael Martin
FOU | Founder | 52 | 16-06-93 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 29-04-19 |
Robert Foster
FOU | Founder | 65 | 16-06-93 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Robert Foster
FOU | Founder | 65 | 16-06-93 |
R. MacKay-Dunn
BRD | Director/Board Member | 73 | 26-06-19 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 29-04-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-1,43% | 104 mld. | |
+8,96% | 105 mld. | |
+4,40% | 22,94 mld. | |
-12,15% | 22,34 mld. | |
-4,36% | 19,25 mld. | |
-39,98% | 17,08 mld. | |
-10,04% | 16,96 mld. | |
+6,79% | 14,16 mld. | |
+38,61% | 12,63 mld. |